T. Rowe Price Associates
CTNM

T. Rowe Price Associates’s Contineum Therapeutics CTNM Stock Holding History

T. Rowe Price Associates’s Portfolio CTNM Stock Details CTNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$552K Buy
33,665
+22,365
+198% +$293K ﹤0.01% 2581
2026
Q1 		$148K Hold
11,300
– – ﹤0.01% 2918
2025
Q4 		$130K Buy
+11,300
New +$129K ﹤0.01% 2911

Other funds holding CTNM

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

T. Rowe Price Associates's CTNM Position: Q2 2026 in Review

T. Rowe Price Associates increased its Contineum Therapeutics (CTNM) stake by 198% in Q2 2026, buying an estimated $293K and bringing the position to 33,665 shares worth $552K. The position accounts for ﹤0.01% of the portfolio, ranked #2581.

T. Rowe Price Associates first reported a position in CTNM in Q4 2025 and has held it in 3 quarters since. 102 funds tracked by Wall St. Rank hold CTNM as of Q2 2026.

  • T. Rowe Price Associates held 33,665 shares of Contineum Therapeutics worth $552K as of Q2 2026.
  • T. Rowe Price Associates bought 22,365 Contineum Therapeutics shares in Q2 2026, an estimated $293K.
  • Contineum Therapeutics made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #2581 holding.
  • T. Rowe Price Associates first reported a position in Contineum Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 102 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.